
Dyne Therapeutics (DYN) Stock Forecast & Price Target
Dyne Therapeutics (DYN) Analyst Ratings
Bulls say
Dyne Therapeutics is a clinical-stage neuromuscular disease company that focuses on developing therapeutics for individuals with genetically-driven neuromuscular diseases. The company's FORCE platform is designed to overcome limitations in delivering treatment to muscle tissue and the central nervous system. Dyne has a strong pipeline, including its lead candidate Z-rostudirsen, which has the potential for US sales of $900M in 2036. Additionally, the company's low-risk, high-reward candidate has the potential for significant success in the treatment of Duchenne's muscular dystrophy (DMD). With a strong IP portfolio and a global confirmatory Phase 3 trial scheduled for 2Q26, Dyne Therapeutics is well-positioned for future growth and success in the rare disease market.
Bears say
Dyne Therapeutics is a clinical-stage neuromuscular disease company focused on developing targeted therapeutics for genetically driven neuromuscular diseases. Despite the potential in its unique FORCE platform, the company is still in the early stages of development and faces significant competition in the rapidly advancing field of gene therapy and oligonucleotide therapeutics. With a current focus on DMD and DM1, the success of Dyne's pipeline will depend heavily on the outcome of its clinical trials and its ability to secure regulatory approvals. Given these risks and uncertainties, the potential for negative outcomes is significant, impacting the company's financial performance and valuation.
This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Dyne Therapeutics (DYN) Analyst Forecast & Price Prediction
Start investing in Dyne Therapeutics (DYN)
Order type
Buy in
Order amount
Est. shares
0 shares